Back to Journals » Therapeutics and Clinical Risk Management » Volume 4 » Issue 2

Prevention of chemotherapy-induced nausea and vomiting: focus on fosaprepitant

Authors Olver IN

Published 11 April 2008 Volume 2008:4(2) Pages 501—506

DOI https://doi.org/10.2147/TCRM.S2345

Ian N Olver

The Cancer Council Australia, Sydney, New South Wales, Australia

Abstract: Fosaprepitant is a prodrug of aprepitant, a neurokinin1 (NK1) receptor antagonist used in prophylactic antiemetic regimens used prior to cytotoxic chemotherapy. Fosaprepitant is being developed to provide a parenterally administered alternative to the orally administered aprepitant. Fosaprepitant is rapidly converted to aprepitant and an intravenous dose of 115 mg is bioequivalent to 125 mg orally, with similar plasma concentrations at 24 hours. In phase I and II trials fosaprepitant shows efficacy, but the large randomized efficacy studies have utilized aprepitant. When it is added to dexamethasone and a 5HT3 receptor antagonist on day 1 prior to chemotherapy aprepitant improves the control of acute post chemotherapy emesis and when continued on days 2 and 3 with dexamethasone it demonstrated even greater improvement in the control of delayed emesis. This has been shown with both cisplatin-containing regimens and those based upon cyclophosphamide and an anthracycline. Fosaprepitant is well tolerated with mild to moderate venous irritation being the only additional toxicity to those seen with oral aprepitant, and that is a function of dose, concentration, and infusion rate. Headaches are the other toxicity most commonly reported. Fosaprepitant can be used as a parenteral alternative to aprepitant in regimens to control chemotherapy-induced emesis.

Keywords: fosaprepitant, aprepitant, neurokinin1 receptor, emesis, chemotherapy

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF] 

 

Readers of this article also read:

Genetic association between the dopamine D1-receptor gene and paranoid schizophrenia in a northern Han Chinese population

Yao J, Ding M, Xing JX, Xuan JF, Pang H, Pan YQ, Wang BJ

Neuropsychiatric Disease and Treatment 2014, 10:645-652

Published Date: 17 April 2014

Is higher body temperature beneficial in ischemic stroke patients with normal admission CT angiography of the cerebral arteries?

Kvistad CE, Khanevski A, Nacu A, Thomassen L, Waje-Andreassen U, Naess H

Vascular Health and Risk Management 2014, 10:49-54

Published Date: 21 January 2014

Vinflunine in the treatment of bladder cancer

Mark Bachner, Maria De Santis

Therapeutics and Clinical Risk Management 2008, 4:1243-1253

Published Date: 5 December 2008

Effects of extracted soy isoflavones alone on blood total and LDL cholesterol: Meta-analysis of randomized controlled trials

Kyoko Taku, Keizo Umegaki, Yoshiko Ishimi, Shaw Watanabe

Therapeutics and Clinical Risk Management 2008, 4:1097-1103

Published Date: 10 October 2008

Treatment of atopic dermatitis with pimecrolimus – impact on quality of life

Hae-Hyuk Lee, Torsten Zuberbier, Margitta Worm

Therapeutics and Clinical Risk Management 2007, 3:1021-1026

Published Date: 15 January 2008

Obstructive sleep apnea and cardiovascular risk

Punginathn Dorasamy

Therapeutics and Clinical Risk Management 2007, 3:1105-1111

Published Date: 15 January 2008